Evidence map›Paper›PMID 32957957›Full record

ArticleRespiratory research2020

Identification of lipid biomarker from serum in patients with chronic obstructive pulmonary disease.

Ding Liu, Maureen Meister, Shiying Zhang, Chi-In Vong, Shuaishuai Wang, Ruixie Fang, Lei Li, Peng George Wang, Pierre Massion, Xiangming Ji

Abstract readMulticenter Study
In one paragraph

Article in Respiratory research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Linking Lipid Metabolism and Immune Function: New Insights into Chronic Respiratory Diseases.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025
    Review
  9. Article
  10. Review
  11. Review
  12. Advances in metabolomics of chronic obstructive pulmonary disease.Chinese medical journal pulmonary and critical care medicine · 2023
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ding LiuDepartment of Chemistry, Georgia State University, Atlanta, GA, 30303, USA.
Maureen MeisterDepartment of Chemistry, Georgia State University, Atlanta, GA, 30303, USA.
Shiying ZhangDepartment of Chemistry, Georgia State University, Atlanta, GA, 30303, USA.
Chi-In VongDepartment of Nutrition, Georgia State University, Atlanta, 30302, USA.
Shuaishuai WangDepartment of Chemistry, Georgia State University, Atlanta, GA, 30303, USA.
Ruixie FangDepartment of Mathematics and Statistics, Georgia State University, Atlanta, GA, 30302, USA.
Lei LiDepartment of Chemistry, Georgia State University, Atlanta, GA, 30303, USA.
Peng George WangDepartment of Chemistry, Georgia State University, Atlanta, GA, 30303, USA.
Pierre MassionCancer Early Detection and Prevention Initiative, Vanderbilt Ingram Cancer Center; Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA.
Xiangming JiDepartment of Chemistry, Georgia State University, Atlanta, GA, 30303, USA. xji4@gsu.edu.ORCID http://orcid.org/0000-0002-5941-0253

Funding

Molecular Approaches to Early Detection of Lung CancerR01CA102353 · NCI · VANDERBILT UNIVERSITY · PI MASSION, PIERRE P. · 2005 to 2014
$2.4M
NCI NIH HHS CA102353NCI NIH HHS R01 CA102353
6 · The paper itself

Abstract

backgroundChronic obstructive pulmonary disease (COPD) is the third leading cause of death in the United States with no effective treatment. The current diagnostic method, spirometry, does not accurately reflect the severity of COPD disease status. Therefore, there is a pressing unmet medical need to develop noninvasive methods and reliable biomarkers to detect early stages of COPD. Lipids are the fundamental components of cell membranes, and dysregulation of lipids was proven to be associated with COPD. Lipidomics is a comprehensive approach to all the pathways and networks of cellular lipids in biological systems. It is widely used for disease diagnosis, biomarker identification, and pathology disorders detection relating to lipid metabolism.

methodsIn the current study, a total of 25 serum samples were collected from 5 normal control subjects and 20 patients with different stages of COPD according to the global initiative for chronic obstructive lung disease (GOLD) (GOLD stages I ~ IV, 5 patients per group). After metabolite extraction, lipidomic analysis was performed using electrospray ionization mass spectrometry (ESI-MS) to detect the serum lipid species. Later, the comparisons of individual lipids were performed between controls and patients with COPD. Orthogonal projections to latent structures discriminant analysis (OPLS-DA) and receiver operating characteristic (ROC) analysis were utilized to test the potential biomarkers. Finally, correlations between the validated lipidomic biomarkers and disease stages, age, FEV1% pack years and BMI were evaluated.

resultsOur results indicate that a panel of 50 lipid metabolites including phospholipids, sphingolipids, glycerolipids, and cholesterol esters can be used to differentiate the presence of COPD. Among them, 10 individual lipid species showed significance (p < 0.05) with a two-fold change. In addition, lipid ratios between every two lipid species were also evaluated as potential biomarkers. Further multivariate data analysis and receiver operating characteristic (ROC: 0.83 ~ 0.99) analysis suggest that four lipid species (AUC:0.86 ~ 0.95) and ten lipid ratios could be potential biomarkers for COPD (AUC:0.94 ~ 1) with higher sensitivity and specificity. Further correlation analyses indicate these potential biomarkers were not affected age, BMI, stages and FEV1%, but were associated with smoking pack years.

conclusionUsing lipidomics and statistical methods, we identified unique lipid signatures as potential biomarkers for diagnosis of COPD. Further validation studies of these potential biomarkers with large population may elucidate their roles in the development of COPD.

Indexed as

AgedAged, 80 and overBiomarkersFemaleHumansLipid MetabolismLipidomicsMaleMiddle AgedPulmonary Disease, Chronic ObstructiveSpectrometry, Mass, Electrospray IonizationBiomarkersBiomarkersChronic obstructive pulmonary disease (COPD)LipidomicsOPLS-DAReceiver operating characteristic

Identifiers

PMID32957957
PMCPMC7507726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.